
Fig. 1

A


Testis
Placenta
Brain
Lung
Breast
Colon
Liver
Stomach
Kidney
Prostate
Pancreas
Ovary
Spleen
Skin
Myocard
Endometrium
PBMCs
Breast cancer
Breast cancer
Cancer cell lines
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

B



Relative expression
100000
10000
1000
100
10
1
Normal tissues
Breast cancer

Fig. 1



Relative expression
100000
10000
1000
100
10
1
COLO-205
LOVO
HCT-15
HT-29
SW-480
LS1034
HCT-116
SW-620
LS174T
LCLC-103H
SHP-77
SK-MES-1
NCI-H522
LOU-NH91
NCI-H187
NCI-H378
CPC-N
FU-OV1
TOV-112D
CAOV-3
EFO-27
EFO-21
A2780
TOV-21G
OVCAR-3
SK-MEL-37
MEL-HO
MEL-USO
Rurowsky
PC-3
LnCaP
DU-145
MDA-Pca-2b
MDA-MB-435S
BT-549
SK-BR-3
MDA-MB-468
MCF-7
MDA-MB-231
HeLa
Colon
Lung
Ovary
Melanoma
Prostate
Breast
Cervix

Fig. 1




D
Relative expression (%)
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
siRNA#2
MCF-7
BT-549
E
untreated
ns-siRNA
siRNA#1
siRNA#2
GT468
Aktin
MCF-7
GT468
Aktin
BT-549
F
Breast
Lung
Colon
Liver
Brain
Testis
Placenta
Breast-Ca
GT468
Aktin
G

Fig. 2






Fig. 3



A
Chemokinesis (%)
140
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
MCF-7
BT-549
B
Chemotaxis (%)
140
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
MCF-7
BT-549
C
Invasion (%)
140
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
MCF-7
BT-549

Fig. 4



A
120
100
80
60
40
20
0
Proliferation (%)
untreated
ns-siRNA
siRNA#1
siRNA#2
MCF-7
BT-549
B
100
80
60
40
20
0
Cells (%)
MCF-7
BT-549
untreated
ns-siRNA
siRNA#1
siRNA#2
G0/G1
S
G2/M
G0/G1
S
G2/M
C
MCF-7
BT-549
1
10
100
1000
FL4-H:: Annexin
1
10
100
1000
FL4-H:: Annexin
Camptothecin
untreated
ns-siRNA
siRNA#1
siRNA#2

Fig. 5






untreated
control Ab
anti-GT468
BT-549
MCF-7
Proliferation (%)
120
100
80
60
40
20
0
0
1
2
4
µg/ml

Fig. 6


A
Cyclin D1
Relative expression (%)
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
siRNA#2
MCF-7
BT-549


B
untreated
ns-siRNA
siRNA#1
siRNA#2
Cyclin D1
Aktin
MCF-7
Cyclin D1
Aktin
BT-549


C
untreated
ns-siRNA
siRNA#1
pAKT
AKT
Actin
MCF-7
pAKT
AKT
Actin
BT-549



D
untreated
control Ab
anti-GT468
pAKT
AKT
Actin
MCF-7
pAKT
AKT
Actin
BT-549

Fig. 7



Peptide ELISA
specific peptide
control peptide
absorbtion
1,80
1,60
1,40
1,20
1,00
0,80
0,60
0,40
0,20
0,00
4E9 1H9
9B6 2A9
59D6 2F2
61C11 2B5
78H11 1H6
supernatant

Fig. 8



GT468-eGFP
hybridoma supernatant
merge
4E9 1H9
9B6 2A9
59D6 2F2

Fig. 9



Proliferation Inhibition
4E9 1H9
9B6 2A9
59D6 2F2
proliferation (%)
120
100
80
60
40
20
0
BT-549
Caov-3
EFO-21
MCF-7
MDA-MB-231
cell lines

Fig. 10



A
CrELISA
GT468 lysate
mock lysate
E405
1,8
1,6
1,4
1,2
1,0
0,8
0,6
0,4
0,2
0,0
22-1A-1
22-2A-1
22-9B-1
23-33A-1
23-19A-1
supernatant
B
Peptide ELISA
specific peptide
control peptide
E405
1,4
1,2
1
0,8
0,6
0,4
0,2
0
F11#33 F7 D12
4A12 2D4 1A10
4E9 1D12 2D4
supernatant

Fig. 11



22-1A-1
22-2A-1
22-9B-1
23-33A-1
23-19A-1
4A12 2D4 1A10
4E9 1D12 2D4
counts
GT468
HEK mock
HEK GT468

Fig. 12


- HEK mock
+ HEK GT468
GT468
22-1A-1
22-2A-1
22-9B-1
23-33A-1
23-19A-1
4A12 2D4 1A10
4E9 1D12 2D4

Fig. 13


Peptide	Sequence
1	MKVFKFIGLMILLTS
2	KFIGLMILLTSAFSA
3	LMILLTSAFSAGSGQ
4	LTSAFSAGSGQSPMT
5	FSAGSGQSPMTVLCS
6	SGQSPMTVLCSIDWF
7	PMTVLCSIDWFMVTV
8	LCSIDWFMVTVHPFM
9	DWFMVTVHPFMLNND
10	VTVHPFMLNNDVCVH
11	PFMLNNDVCVHFHEL
12	NNDVCVHFHELHLGL
13	CVHFHELHLGLGCPP
14	HELHLGLGCPPNHVQ
15	LGLGCPPNHVQPHAY
16	CPPNHVQPHAYQFTY
17	HVQPHAYQFTYRVTE
18	HAYQFTYRVTECGIR
19	FTYRVTECGIRAKAV
20	VTECGIRAKAVSQDM
21	GIRAKAVSQDMVIYS
22	KAVSQDMVIYSTEIH
23	QDMVIYSTEIHYSSK
24	IYSTEIHYSSKGTPS
25	EIHYSSKGTPSKFVI

Peptide	Sequence
26	SSKGTPSKFVIPVSC
27	TPSKFVIPVSCAAPQ
28	FVIPVSCAAPQKSPW
29	VSCAAPQKSPWLTKP
30	APQKSPWLTKPCSMR
31	SPWLTKPCSMRVASK
32	TKPCSMRVASKSRAT
33	SMRVASKSRATAQKD
34	ASKSRATAQKDEKCY
35	RATAQKDEKCYEVFS
36	QKDEKCYEVFSLSQS
37	KCYEVFSLSQSSQRP
38	VFSLSQSSQRPNCDC
39	SQSSQRPNCDCPPCV
40	QRPNCDCPPCVFSEE
41	CDCPPCVFSEEEHTQ
42	PCVFSEEEHTQVPCH
43	SEEEHTQVPCHQAGA
44	HTQVPCHQAGAQEAQ
45	PCHQAGAQEAQPLQP
46	AGAQEAQPLQPSHFL
47	EAQPLQPSHFLDISE
48	LQPSHFLDISEDWSL
49	HFLDISEDWSLHTDD
50	ISEDWSLHTDDMIGS
51	SEDWSLHTDDMIGSM

Hybridoma	Reactivity (Peptide)
22-1A-1	50+51
22-2A-1	18, 26-31, 42
22-9B-1	27, 29-31
23-33A-1	47+48
23-19A-1	48+49

Hybridoma	Reactivity (Sequence)
F11#33 F7 D12	VFSLSQSSQRPNC
4A12 2D4 1A10	APQKSPWLTKPC
4A9 1D12 2D4	APQKSPWLTKPC

Fig. 14


Proliferation (%)
0
20
40
60
80
100
120
SK-BR-3 (72h)
control
4A12 2D4 1A10
MCF-7 (120h)
15µg/ml
45µg/ml
control
4E9 1D12 2D4